Join us for UroGen Pharma’s KOL Event, featuring presentations from experts Gary D. Steinberg, MD (NYU Grossman School of Medicine) and William C. Huang, MD (NYU Langone Health) who will discuss the current treatment landscape and unmet medical needs of non-muscle invasive bladder cancer (NMIBC).

UroGen leadership will provide insight into their pipeline portfolio, highlighting their Phase 3 asset UGN-102, an investigational formulation that utilizes UroGen’s innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade intermediate-risk NMIBC.

A live Q&A session will follow the formal presentations.